Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · Real-Time Price · USD
18.55
-0.15 (-0.80%)
At close: Dec 5, 2025, 4:00 PM EST
19.59
+1.04 (5.61%)
After-hours: Dec 5, 2025, 5:40 PM EST

Theravance Biopharma Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2015
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2015
Market Capitalization
9404635607558141,137
Upgrade
Market Cap Growth
101.41%-17.33%-25.82%-7.35%-28.37%-22.63%
Upgrade
Enterprise Value
6524164773201,2691,398
Upgrade
Last Close Price
18.559.4111.2411.2211.0517.77
Upgrade
PE Ratio
31.97--0.87--
Upgrade
PS Ratio
11.537.199.7514.7014.7215.82
Upgrade
PB Ratio
4.042.642.631.71-2.40-3.74
Upgrade
P/TBV Ratio
4.042.642.631.71--
Upgrade
EV/Sales Ratio
8.126.478.306.2322.9519.46
Upgrade
Debt / Equity Ratio
0.190.280.230.12-1.98-2.23
Upgrade
Asset Turnover
0.210.180.120.110.130.16
Upgrade
Quick Ratio
9.304.894.8411.993.202.93
Upgrade
Current Ratio
9.485.025.3912.314.263.18
Upgrade
Return on Equity (ROE)
14.03%-29.04%-16.86%-179.84%--
Upgrade
Return on Assets (ROA)
-5.32%-7.21%-6.78%-10.07%-35.20%-42.38%
Upgrade
Return on Capital (ROIC)
-8.08%-10.88%-8.87%-11.99%-42.23%-56.44%
Upgrade
Return on Capital Employed (ROCE)
-8.70%-13.20%-15.00%-13.70%-75.10%-86.10%
Upgrade
Earnings Yield
3.12%-12.19%-9.86%115.58%-24.49%-24.45%
Upgrade
FCF Yield
25.90%-2.56%-5.27%-24.86%-25.94%-22.61%
Upgrade
Buyback Yield / Dilution
-3.49%11.67%24.85%-5.95%-11.41%-12.11%
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.